BACKGROUND: Central nervous system (CNS) metastases represent a major problem in the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer because of the disappointing efficacy of HER2-targeted therapies against brain lesions. The antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) has shown efficacy in trastuzumab-resistant systemic breast cancer. Here, we tested the hypothesis that T-DM1 could overcome trastuzumab resistance in murine models of brain metastases. METHODS: We treated female nude mice bearing BT474 or MDA-MB-361 brain metastases (n = 9-11 per group) or cancer cells grown in organotypic brain slice cultures with trastuzumab or T-DM1 at equivalent or equipotent doses. Using intravital imaging, molecular techniques and histological analysis we determined tumor growth, mouse survival, cancer cell apoptosis and proliferation, tumor drug distribution, and HER2 signaling. Data were analyzed with one-way analysis of variance (ANOVA), Kaplan-Meier analysis, and Coefficient of Determination. All statistical tests were two-sided. RESULTS: T-DM1 delayed the growth of HER2-positive breast cancer brain metastases compared with trastuzumab. These findings were consistent between HER2-driven and PI3K-driven tumors. The activity of T-DM1 resulted in a survival benefit (median survival for BT474 tumors: 28 days for trastuzumab vs 112 days for T-DM1, hazard ratio = 6.2, 95% confidence interval = 6.1 to 85.84, P < .001). No difference in drug distribution or HER2-signaling was revealed between the two groups. However, T-DM1 led to a statistically significant increase in tumor cell apoptosis (one-way ANOVA for ApopTag, P < .001), which was associated with mitotic catastrophe. CONCLUSIONS: T-DM1 can overcome resistance to trastuzumab therapy in HER2-driven or PI3K-driven breast cancer brain lesions due to the cytotoxicity of the DM1 component. Clinical investigation of T-DM1 for patients with CNS metastases from HER2-positive breast cancer is warranted.
BACKGROUND: Central nervous system (CNS) metastases represent a major problem in the treatment of humanepidermal growth factor receptor 2 (HER2)-positive breast cancer because of the disappointing efficacy of HER2-targeted therapies against brain lesions. The antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) has shown efficacy in trastuzumab-resistant systemic breast cancer. Here, we tested the hypothesis that T-DM1 could overcome trastuzumab resistance in murine models of brain metastases. METHODS: We treated female nude mice bearing BT474 or MDA-MB-361 brain metastases (n = 9-11 per group) or cancer cells grown in organotypic brain slice cultures with trastuzumab or T-DM1 at equivalent or equipotent doses. Using intravital imaging, molecular techniques and histological analysis we determined tumor growth, mouse survival, cancer cell apoptosis and proliferation, tumor drug distribution, and HER2 signaling. Data were analyzed with one-way analysis of variance (ANOVA), Kaplan-Meier analysis, and Coefficient of Determination. All statistical tests were two-sided. RESULTS:T-DM1 delayed the growth of HER2-positive breast cancer brain metastases compared with trastuzumab. These findings were consistent between HER2-driven and PI3K-driven tumors. The activity of T-DM1 resulted in a survival benefit (median survival for BT474 tumors: 28 days for trastuzumab vs 112 days for T-DM1, hazard ratio = 6.2, 95% confidence interval = 6.1 to 85.84, P < .001). No difference in drug distribution or HER2-signaling was revealed between the two groups. However, T-DM1 led to a statistically significant increase in tumor cell apoptosis (one-way ANOVA for ApopTag, P < .001), which was associated with mitotic catastrophe. CONCLUSIONS:T-DM1 can overcome resistance to trastuzumab therapy in HER2-driven or PI3K-driven breast cancer brain lesions due to the cytotoxicity of the DM1 component. Clinical investigation of T-DM1 for patients with CNS metastases from HER2-positive breast cancer is warranted.
Authors: Sunil Verma; David Miles; Luca Gianni; Ian E Krop; Manfred Welslau; José Baselga; Mark Pegram; Do-Youn Oh; Véronique Diéras; Ellie Guardino; Liang Fang; Michael W Lu; Steven Olsen; Kim Blackwell Journal: N Engl J Med Date: 2012-10-01 Impact factor: 91.245
Authors: Johanna C Bendell; Susan M Domchek; Harold J Burstein; Lyndsay Harris; Jerry Younger; Irene Kuter; Craig Bunnell; Montse Rue; Rebecca Gelman; Eric Winer Journal: Cancer Date: 2003-06-15 Impact factor: 6.860
Authors: Nancy U Lin; Véronique Diéras; Devchand Paul; Dominique Lossignol; Christos Christodoulou; Hans-Joachim Stemmler; Henri Roché; Minetta C Liu; Richard Greil; Eva Ciruelos; Sibylle Loibl; Stefania Gori; Andrew Wardley; Denise Yardley; Adam Brufsky; Joanne L Blum; Stephen D Rubin; Bernie Dharan; Klaudia Steplewski; Denise Zembryki; Cristina Oliva; Debasish Roychowdhury; Paolo Paoletti; Eric P Winer Journal: Clin Cancer Res Date: 2009-02-15 Impact factor: 12.531
Authors: Wende Li; Yujiao Liu; Weining Yang; Xiaoxing Han; Sen Li; Hao Liu; Leo E Gerweck; Dai Fukumura; Jay S Loeffler; Burton B Yang; Rakesh K Jain; Peigen Huang Journal: J Neurooncol Date: 2017-10-28 Impact factor: 4.130
Authors: Jessica A Carr; Daniel Franke; Justin R Caram; Collin F Perkinson; Mari Saif; Vasileios Askoxylakis; Meenal Datta; Dai Fukumura; Rakesh K Jain; Moungi G Bawendi; Oliver T Bruns Journal: Proc Natl Acad Sci U S A Date: 2018-04-06 Impact factor: 11.205
Authors: David P Kodack; Vasileios Askoxylakis; Gino B Ferraro; Qing Sheng; Mark Badeaux; Shom Goel; Xiaolong Qi; Ram Shankaraiah; Z Alexander Cao; Rakesh R Ramjiawan; Divya Bezwada; Bhushankumar Patel; Yongchul Song; Carlotta Costa; Kamila Naxerova; Christina S F Wong; Jonas Kloepper; Rita Das; Angela Tam; Jantima Tanboon; Dan G Duda; C Ryan Miller; Marni B Siegel; Carey K Anders; Melinda Sanders; Monica V Estrada; Robert Schlegel; Carlos L Arteaga; Elena Brachtel; Alan Huang; Dai Fukumura; Jeffrey A Engelman; Rakesh K Jain Journal: Sci Transl Med Date: 2017-05-24 Impact factor: 17.956
Authors: Sheheryar Kabraji; Jing Ni; Nancy U Lin; Shaozhen Xie; Eric P Winer; Jean J Zhao Journal: Clin Cancer Res Date: 2018-02-06 Impact factor: 12.531
Authors: Brunilde Gril; Debbie Wei; Alexandra S Zimmer; Christina Robinson; Imran Khan; Simone Difilippantonio; Michael G Overstreet; Patricia S Steeg Journal: Neuro Oncol Date: 2020-11-26 Impact factor: 12.300
Authors: Costas D Arvanitis; Vasileios Askoxylakis; Yutong Guo; Meenal Datta; Jonas Kloepper; Gino B Ferraro; Miguel O Bernabeu; Dai Fukumura; Nathan McDannold; Rakesh K Jain Journal: Proc Natl Acad Sci U S A Date: 2018-08-27 Impact factor: 11.205
Authors: Vasileios Askoxylakis; Mark Badeaux; Sylvie Roberge; Ana Batista; Ned Kirkpatrick; Matija Snuderl; Zohreh Amoozgar; Giorgio Seano; Gino B Ferraro; Sampurna Chatterjee; Lei Xu; Dai Fukumura; Dan G Duda; Rakesh K Jain Journal: Nat Protoc Date: 2017-10-05 Impact factor: 13.491